The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Friday, August 14, 2026

Subject of the day

BAYN.DE

Concerning the House

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Germany · www.bayer.com

The Ledger
LineMar 2025Jun 2025Sep 2025Dec 2025
Revenue$13.74B$10.74B$9.66B$11.44B
Gross profit$8.11B$6.38B$5.35B$6.94B
Operating income$2.32B$13.00M-$543.00M$4.34B
Net income$1.30B-$199.00M-$963.00M-$3.76B
Diluted EPS1.32-0.20-0.98
Free cash flow-$1.40B$593.00M$849.00M$3.40B
CapEx-$388.00M-$465.00M-$836.00M-$798.00M
Quotation

$48.06

+0.06 (+0.1%)

52w hi$53.36
52w lo$25.98
Vol1.59M
As ofAug 13
The Verdict

Hold

Our score -0.12

Short-0.00
Medium-0.02
Long-0.56

computed 2026-08-13

By the Numbers

Bayer Aktiengesellschaft

Healthcare · Drug Manufacturers - General

Market cap$47.22B
Enterprise value$80.63B
Trailing P/E
Forward P/E10.09x
EV / EBITDA7.96x
P / S (ttm)1.04x
Profit margin-3.8%
Return on equity-5.7%
Revenue growth+1.2%
Earnings growth
Debt / equity129.36
Risk Metrics
Beta vs SPX0.11
Corr SPX0.04
Annual vol41.1%
Annual ret+35.5%
Sharpe0.86
Max DD-38.7%

Window: 504 trading days (489 obs)

Layer Breakdown
LayerRawContribution
Fundamental-0.13
Sector+0.12
Technical+0.00
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$47.85$48.36$47.85$48.061.59M
Aug 12$48.95$49.09$47.79$48.001.85M
Aug 11$49.00$49.40$48.55$48.951.60M
Aug 10$50.18$50.26$48.97$49.232.01M
Aug 7$49.42$50.44$49.21$49.812.29M